Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Supernus PharmaceuticalsLTS:0LB2 +2.22%85 Shiller PE Ratio is 30.33 as of Sep. 15, 2026, which is 0% above its 10-year median of 30.23. GuruFocus rates LTS:0LB2 with a GF Score™ of 85/100 and a GF Value™ of $44.47 (Fairly Valued). The stock has 1 warning sign investors should review. Among 529 Drug Manufacturers companies, Supernus Pharmaceuticals ranks worse than 59.92% on this metric.
The historical rank and industry rank for Supernus Pharmaceuticals's Shiller PE Ratio or its related term are showing as below:
LTS:0LB2'
s Shiller PE Ratio Range Over the Past 10 Years
Min: 17.35 Med: 30.23 Max: 79.92
Current: 29.02
During the past years, Supernus Pharmaceuticals's highest Shiller PE Ratio was 79.92. The lowest was 17.35. And the median was 30.23.
LTS:0LB2's Shiller PE Ratio is ranked worse than 59.92% of 529
companies
in the Drug Manufacturers industry
Industry Median: 24.61
vs LTS:0LB2: 29.02
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Supernus Pharmaceuticals's adjusted earnings per share data for the three months ended in Jun. 2026 was $-1.005. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $1.40 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Supernus Pharmaceuticals (LTS:0LB2) Shiller PE Ratio Explanation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Supernus Pharmaceuticals Shiller PE Ratio Related Terms
Supernus Pharmaceuticals Shiller PE Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0LB2 vs BCRX, PBH, RGC: Shiller PE Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Supernus Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Supernus Pharmaceuticals Shiller PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Supernus Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Supernus Pharmaceuticals's Shiller PE Ratio falls into.
Supernus Pharmaceuticals Shiller PE Ratio Calculation
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Supernus Pharmaceuticals (LTS:0LB2) has a Shiller PE Ratio of 30.33 as of Sep. 15, 2026. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Supernus Pharmaceuticals and its competitors. This is near median its historical median of 30.23. Over the past decade, Supernus Pharmaceuticals' Shiller PE Ratio has ranged from 17.35 to 79.92. According to the industry distribution chart, Supernus Pharmaceuticals ranks #317 out of 529 companies in the Drug Manufacturers industry, placing it in the top 59.9%.
Is Supernus Pharmaceuticals' Shiller PE Ratio too high?
Supernus Pharmaceuticals' current Shiller PE Ratio of 30.33 is near median its 10-year median of 30.23. Over the past 10 years, this metric has ranged from a low of 17.35 to a high of 79.92. The Drug Manufacturers industry median Shiller PE Ratio is 24.61. Supernus Pharmaceuticals' value of 30.33 is 23.2% above this industry median. Based on the distribution chart, Supernus Pharmaceuticals ranks #317 out of 529 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Supernus Pharmaceuticals has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Supernus Pharmaceuticals' Shiller PE Ratio compare to BCRX and PBH?
According to the Drug Manufacturers industry distribution chart, Supernus Pharmaceuticals ranks #317 out of 529 companies for Shiller PE Ratio. This places Supernus Pharmaceuticals in the lower half of its industry. The industry median Shiller PE Ratio is 24.61. Supernus Pharmaceuticals' value of 30.33 is 23.2% above this benchmark. Historically, Supernus Pharmaceuticals' own Shiller PE Ratio has ranged from 17.35 to 79.92 over the past decade. While the company's 10-year median is 30.23 vs. the industry median of 24.61, Supernus Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shiller PE Ratio for a Drug Manufacturers company?
The median Shiller PE Ratio among Drug Manufacturers companies is 24.61, based on 529 companies in the industry. Companies in the top quartile (top 25%) have a Shiller PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Shiller PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Supernus Pharmaceuticals's current Shiller PE Ratio of 30.33 is 23.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shiller PE Ratio mean?
A high Shiller PE Ratio can signal that a stock is expensive relative to its fundamentals. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Supernus Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Shiller PE Ratio is 24.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Supernus Pharmaceuticals's current Shiller PE Ratio is 30.33, which is near median its own 10-year median of 30.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supernus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Supernus Pharmaceuticals (LTS:0LB2) is currently considered Fairly Valued. The stock's GF Value™ is $44.47, compared to a current price of $42.37 — trading 4.7% below its estimated fair value. The current Shiller PE Ratio is 30.33, which is near median its 10-year median of 30.23 and 23.2% above the Drug Manufacturers industry median of 24.61. Supernus Pharmaceuticals' overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shiller PE Ratio calculated?
Shiller PE Ratio is calculated from a company's financial statements. For Supernus Pharmaceuticals (LTS:0LB2), the current Shiller PE Ratio is 30.33 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Supernus Pharmaceuticals (LTS:0LB2) Overvalued in 2026?
Based on GuruFocus' analysis, Supernus Pharmaceuticals stock appears to be undervalued.
The current stock price of $42.37 is trading 4.7% below its estimated GF Value™ of $44.47.
GuruFocus considers Supernus Pharmaceuticals to be Fairly Valued.
Key valuation signals for LTS:0LB2:
Shiller PE Ratio: 30.33 (near median its 10-year median of 30.23)
GF Value™: $44.47 vs. price of $42.37 (4.7% below fair value)
Industry Position: 23.2% above the Drug Manufacturers median (#317 of 529)
No single metric tells the full story. See the LTS:0LB2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
85GF Score
Get the complete analysis for LTS:0LB2
Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0LB2 has been successfully added to your 
